In short, the answer is negative, as we found in our study published in the Journal of Cancer Policy. Our analysis also revealed other interesting findings.
Thank you for your work! These types of studies are essential. Your point about single-arm trials is very good. I would bet you could find good material to use in further study regarding single-arm trials and how these affect different areas of pharmacy and other domains of medicine, economics, etc.
Thanks for the work you do exposing greed in the onc pharma industry and for summarizing it in this article. We need more people like you to help make change in a very flawed system. Keep up the great work!
I would be interested to see the results subset by drug type. Biologics and cell therapy is new on the scene and more expensive than small molecules which may confound results.
Thank you for your work! These types of studies are essential. Your point about single-arm trials is very good. I would bet you could find good material to use in further study regarding single-arm trials and how these affect different areas of pharmacy and other domains of medicine, economics, etc.
Thanks for the work you do exposing greed in the onc pharma industry and for summarizing it in this article. We need more people like you to help make change in a very flawed system. Keep up the great work!
very interesting!
I noticed you used WAC, or list, prices.
'Notably, both Part D and B figures exclude rebates or concessions'.
Do you have any sense for how the conclusions would have changed if you used the net price number?
I would be interested to see the results subset by drug type. Biologics and cell therapy is new on the scene and more expensive than small molecules which may confound results.